With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Rate control, rhythm control, new drugs and devices for anticoagulation -- the armamentarium of treatment options is expanding rapidly. Drs. Yancy, Cannon, and Boehmer discuss the latest treatment modalities for patients with AF.
This review discusses risk factors of AF, the influence of AF on outcomes, and highlights recent data suggesting that secondary prevention of AF may help to reduce the burden of the arrhythmia.
AF is sometimes considered a benign or nuisance condition. However, it is vital that it is recognized as a harbinger of underlying cardiovascular disease, and that it is diagnosed early and treated appropriately. Join Drs. Kirchhof, Dorian, Marrouche, and Steg as they discuss strategies to reduce the complications of AF.
The ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation were published in 2006. Since this publication, new data and treatment options have been developed. Join Drs. Prystowsky, Hohnloser, and Kowey, as they discuss these new data and strategies for implementation in clinical practice.
Hypertension plays a key role in the pathogenesis of atrial fibrillation. Join our expert panel, Drs. Agabiti-Rosei, Allessie, Crijns, Israel, and Weber for a discussion of the current data and treatment options for optimal management and improving outcomes in hypertensive patients with AF.
The association between stroke and AF has been well established. Join Drs. Diener, Norrving, Torp-Pedersen, and Sacco, as they present new data from the 2009 EuroStroke meeting in Stockholm, Sweden, for preventing stroke and improving outcomes in patients with AF.
AF is the leading cause of arrhythmia-related hospitalizations and affects nearly 7 million people in the United States and Europe. Please join Drs. Dorian, Curtis, and Hohnloser for a discussion on strategies to reduce hospitalization rates for patients with AF.
AF is the most common sustained arrhythmia and significantly increases an individual's risk for heart failure. Join our expert panel: Drs. Naccarelli, Cannon, and Connolly for an in-depth discussion of new data and management strategies for improving outcomes in patients with AF.
Atrial fibrillation (AF) affects almost 1% of the adult population in the United States. Join our experts Drs. Hohnloser, Prystowsky, and Bhatt as they discuss recently published results of new data from the ATHENA trial and how this data will impact care for patients with AF.
The morbidity and mortality associated with AF is substantial and treatment of these patients needs to be improved. In this program, leading experts in cardiology discuss among other issues, rate vs rhythm control, new clinical trial data, and current treatment options.
Cardioembolic stroke is a frequent, devastating consequence of atrial fibrillation (AF). Drs Cohen and Sacco discuss current management and prevention strategies from a cardiology and neurology perspective, followed by Dr Connolly who addresses new clinical trial data on stroke in rhythm-managed AF patients.
Acknowledgements
CME provider: MedscapeCME.
The Advances in Atrial Fibrillation clinical theme is supported by an independent educational grant from sanofi-aventis.
Steering committee
The steering committee members are active in overseeing the development and direction of this educational series.